证券代码：002566 证券简称：益盛药业 吉林省集安益盛药业股份有限公司投资者关系活动记录表 编号：2023-001 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □√ 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人员 姓名 通过"全景•路演天下"（http://ir.p5w.net）参与 2022 年度业绩网上说明会的广大投资者 时间 2023 年 4 月 26 日 地点 全景•路演天下（http://ir.p5w.net） 上市公司接待人员姓 名 总经理 薛晓民 董事会秘书 李铁军 副总经理兼财务总监 毕建涛 独立董事 李明 投资者关系活动主要 内容介绍 公司于 2023 年 4 月 26 日（星期三）下午 15:00-17:00 在 全景网举行 2022 年度业绩网上说明会，本次年度业绩说 明会采用网络远程的方式举行，说明会问答环节主要内容 详见附件。 附件清单（如有） 公司 2022 年度业绩网上说明会问题列表 日期 2023 年 4 月 26 日 2、怎么不生产人参口服液，人参糖片，等消费次数多的产品 答: 您好，我公司可生产 ...

Financial Performance - The company's operating revenue for 2022 was ¥830,041,323.93, a decrease of 5.45% compared to ¥877,929,541.89 in 2021[19] - The net profit attributable to shareholders for 2022 was ¥83,096,994.27, down 13.46% from ¥96,020,349.90 in the previous year[19] - The net profit after deducting non-recurring gains and losses was ¥65,668,739.12, reflecting a decline of 21.80% from ¥83,970,880.18 in 2021[19] - The net cash flow from operating activities decreased by 32.19% to ¥145,856,177.19 from ¥215,100,714.73 in 2021[19] - The basic earnings per share for 2022 was ¥0.2511, a decrease of 13.44% compared to ¥0.2901 in 2021[19] - Total assets at the end of 2022 were ¥2,966,606,675.95, an increase of 3.57% from ¥2,864,366,655.13 at the end of 2021[19] - The net assets attributable to shareholders increased by 3.51% to ¥2,154,978,185.80 from ¥2,081,809,739.53 in 2021[19] - The weighted average return on equity for 2022 was 3.92%, down from 4.72% in 2021[19] Revenue Breakdown - Pharmaceutical industry revenue increased by 1.94% to ¥677,932,465.36, accounting for 81.68% of total revenue[46] - Revenue from the cosmetics sector fell by 38.17% to ¥71,900,945.49, representing 8.66% of total revenue[46] - Sales of capsule products decreased by 6.84% to ¥383,662,265.23, while injection products saw a 22.49% increase to ¥264,937,275.59[46] - Sales revenue from health food products reached CNY 74,726,200, a slight decrease of 0.94% year-on-year[43] Research and Development - The company has established collaborations with well-known universities and research institutions to enhance its research and development capabilities[31] - The company developed and launched 5 new health food products during the reporting period, with a total of 16 products in the R&D pipeline[43] - The number of R&D personnel increased by 2.90% to 248 in 2022 from 241 in 2021[56] - The proportion of R&D personnel with a master's degree increased by 200% to 3 in 2022 from 1 in 2021[56] - Total R&D investment amounted to CNY 29,634,086.66 in 2022, a decrease of 21.15% from CNY 37,584,947.77 in 2021, representing 3.57% of operating revenue[57] Product Development and Market Strategy - The company has developed a complete ginseng industry chain, expanding from pharmaceutical production to cosmetics and health foods, with 11 dosage forms and 117 varieties of products[31] - The company aims to leverage modern technology while rooting itself in traditional culture to enhance its ginseng industry chain[31] - The company has developed 500+ cosmetic products, including skincare and makeup, leveraging its ginseng resources and technology[33] - The company aims to enhance its market share in the traditional Chinese medicine sector, focusing on optimizing product structure and increasing sales scale[74] - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 200 million yuan allocated for this purpose[97] Governance and Management - The company governance structure complies with relevant laws and regulations, ensuring effective operation and management[82] - The company has established a performance evaluation and incentive system linking management compensation to performance[83] - The company has a dedicated investor relations management system to ensure accurate and timely communication with investors[84] - The company has a clear asset ownership structure, ensuring no asset or fund occupation by the controlling shareholder[87] - The management team is expected to drive innovation and market expansion in the pharmaceutical sector[90] Environmental and Social Responsibility - The company emphasizes the importance of environmental compliance and may incur additional costs to meet stricter regulations[78] - The company has actively invested in environmental protection and energy-saving initiatives, adhering to relevant environmental regulations[132] - The company donated RMB 4.98 million worth of "Red Ginseng Paste Drink" to the Jilin Provincial Traditional Chinese Medicine Association and RMB 2.457 million worth of ginseng to epidemic prevention personnel in Jilin Province[132] Financial Health and Cash Flow - The company's retained earnings at the end of the reporting period amounted to RMB 846,881,870.12[119] - The net increase in cash and cash equivalents was CNY 123,568,861.36 in 2022, a significant improvement from a decrease of CNY 67,301,498.53 in 2021[59] - The company's total financial assets amounted to approximately CNY 127.35 million, with a decrease of 0.25% compared to the previous period[66] - The company's cash and cash equivalents rose to CNY 343,263,877.76 from CNY 219,695,016.40, showing a significant increase of approximately 56.23%[194] Shareholder Information - The company reported a total shareholding of 132,769,749 shares at the end of the reporting period, with a decrease of 554,900 shares[90] - The company distributed cash dividends of 0.30 RMB per 10 shares, totaling 9,928,548.00 RMB, based on a total share capital of 330,951,600 shares[115] - A cash dividend of RMB 0.50 per share (including tax) will be distributed to shareholders, totaling RMB 16,547,580.00, which represents 100% of the profit distribution[119] Risk Factors - The company faces risks including industry policy adjustments, rising production costs, and R&D risks, as noted in the management discussion[4] - The company faces risks related to industry policy adjustments, rising production costs, and potential talent shortages[76][78]

为充分尊重投资者、提升交流的针对性，现就公司2022年度网上业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月26 日（星期三）下午15:00 前访问 http://ir.p5w.net/zj/或扫描下方二维码，进入 问题征集专题页面。公司将在2022年度网上业绩说明会上，对投资者普遍关注的问 题进行回答。欢迎广大投资者积极参与本次网上业绩说明会。 （问题征集专题页面二维码） 特此公告。 证券代码：002566 证券简称：益盛药业 公告编号：2023-011 吉林省集安益盛药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下简称"公司"）已于2023年4月19日在 巨潮资讯网（www.cninfo.com.cn）披露了《2022年年度报告》。为便于广大投资者 进一步详细了解公司情况，公司定于2023年4月26日（星期三）下午15:00-17:00在 全景网举行2022年度网上业绩说明会。本次说明会将采用网络远程方式举行，投资 ...

证券代码：002566 证券简称：益盛药业 吉林省集安益盛药业股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |-----------------------|----------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 东方国际伍一支；华创证券张伟光；建信基金潘龙玲； 21 世纪 | | 人员姓名 | | 报道谢达斐；国都证券姚巍；宏道投资杨洁；吉渊投资陈杰； | | | | 天弘基金郭相博、刘盟盟；工银瑞信谭冬寒；泰达宏利庞文杰； | | | 中国证券报尹哲辉。 | | | 时间 | 2015 年 6 月 26 | 日 | | 地点 | 北京拉斐特城堡酒店会议中 ...

证券代码：002566 证券简称：益盛药业 吉林省集安益盛药业股份有限公司 投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |----------------|-------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中航证券沈文文、成果 | | | 人员姓名 | | | | 时间 | 2016 年 11 月 3 | 日 | | 地点 | 总经理办公室 | | | 上市公司接待人 | | 总经理薛晓民、证券事务代表丁富君 | | 员姓名 | | | | 投资者关系活动 | | 本次投资者关系活动的主要内容包括：公司人参产业发展规划 | | 主要内容介绍 | | 情况及进展情况，并到人参饮片 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥194,524,452.56, a decrease of 11.04% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥16,521,841.90, down 30.81% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,750,114.65, reflecting a decline of 38.52% compared to the previous year[4] - Total operating costs decreased from ¥592,743,896.16 to ¥557,743,368.96, a reduction of approximately 5.9%[18] - Net profit attributable to shareholders decreased from ¥65,251,454.52 to ¥60,333,857.59, a decline of about 7.5%[19] - Operating profit decreased from ¥88,409,326.92 to ¥77,426,756.64, a drop of approximately 12.3%[18] - Total comprehensive income decreased from ¥74,375,675.38 to ¥65,887,086.43, a decrease of about 11.5%[19] - Basic and diluted earnings per share decreased from ¥0.1972 to ¥0.1823, a decline of approximately 7.5%[19] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period was ¥87,206,481.59, a significant decrease of 46.50% year-on-year[4] - Cash flow from operating activities decreased from ¥163,004,140.39 to ¥87,206,481.59, a decline of about 46.6%[21] - The company's cash and cash equivalents increased by 32.00% to ¥289,992,896.36 due to improved cash flow from operations[8] - Cash and cash equivalents at the end of the period increased to ¥289,992,896.36 from ¥283,417,266.80, an increase of approximately 2.0%[22] - Net cash flow from financing activities showed a net outflow of ¥20,344,523.90 compared to a net outflow of ¥65,898,484.84 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,892,384,151.53, an increase of 0.98% from the end of the previous year[5] - The total assets of the company as of September 30, 2022, amounted to RMB 2,892,384,151.53, up from RMB 2,864,366,655.13 at the start of the year[15] - The total liabilities decreased slightly to RMB 665,388,413.79 from RMB 666,082,205.82, showing a marginal reduction[15] - The company's total equity increased to RMB 2,226,995,737.74 from RMB 2,198,284,449.31, reflecting an increase of approximately 1.3%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,907[10] - The top shareholder, Zhang Yisheng, holds 39.08% of the shares, amounting to 129,348,530 shares[10] Government Subsidies and Non-Recurring Gains - The company received government subsidies amounting to ¥2,314,073.95 during the reporting period, contributing to its non-recurring gains[6] Operational Metrics - Sales revenue from goods and services received cash decreased from ¥769,868,721.37 to ¥685,040,384.37, a decline of approximately 11.0%[20] - Research and development expenses increased from ¥14,891,356.12 to ¥15,482,990.67, an increase of about 3.9%[18] - Accounts receivable rose to RMB 216,225,964.18 from RMB 195,846,007.45, indicating an increase of about 10%[14] - The inventory level remained stable at RMB 1,602,331,661.55, compared to RMB 1,596,871,561.48 at the beginning of the year[14] Corporate Governance - The company is implementing a rectification plan to address issues related to shareholding disclosure, with certain shareholders no longer having shareholding proxies[12] - The company aims to resolve the shareholding proxy issues in the shortest time possible while considering the impact on the secondary market[12] Employee Compensation - The company reported a decrease in employee compensation liabilities to RMB 5,706,420.52 from RMB 7,907,392.07, indicating a reduction of approximately 28%[15]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥428,409,146.26, a decrease of 5.82% compared to ¥454,884,074.49 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was ¥43,812,015.69, an increase of 5.90% from ¥41,371,047.86 year-on-year[25]. - The net cash flow from operating activities decreased by 39.79% to ¥72,426,598.89 from ¥120,294,568.26 in the previous year[25]. - The basic earnings per share increased to ¥0.1324, up 5.92% from ¥0.1250 in the same period last year[25]. - The company reported a decrease of 8.53% in net profit after deducting non-recurring gains and losses, totaling ¥32,817,432.17 compared to ¥35,876,286.87 in the previous year[25]. - The company's total revenue for the reporting period was ¥428,409,146.26, representing a decrease of 5.82% compared to the previous year[47]. - The pharmaceutical sector accounted for 82.01% of total revenue, with a year-on-year increase of 5.50% in this segment[48]. - The total profit for the first half of 2022 was CNY 87,892,527.35, compared to CNY 85,417,906.33 in the previous year, an increase of 2.9%[136]. - The company reported a net increase in cash and cash equivalents of ¥61,534,961.32 for the first half of 2022, contrasting with a decrease of ¥147,545,647.58 in the same period of 2021[142]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,888,592,843.66, reflecting a 0.85% increase from ¥2,864,366,655.13 at the end of the previous year[25]. - The company's total assets as of June 30, 2022, were CNY 2,974,259,795.98, an increase from CNY 2,935,747,364.14 at the beginning of the year[129]. - The total liabilities decreased to CNY 865,192,174.31 from CNY 898,658,750.33 at the start of the year[129]. - The inventory level was ¥1,586,034,217.18, accounting for 54.91% of total assets, showing a slight decrease from the previous year[54]. Research and Development - The company has developed 11 dosage forms and 117 varieties, with 49 products included in the National Basic Medical Insurance Drug List[38]. - The company holds 19 invention patents, 5 design patents, and 4 utility model patents, indicating a strong focus on innovation[45]. - Research and development expenses decreased by 36.99% to ¥13,327,785.79, primarily due to reduced clinical trial costs[47]. - The company has initiated research and development for new technologies aimed at enhancing product offerings[145]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies and products[150]. Market and Business Strategy - The company is expanding its business model to include health foods and cosmetics, forming a complete ginseng industry chain[37]. - The company aims to leverage technological innovation and internal management to ensure sustainable development amidst a challenging market environment[33]. - The company plans to maintain its strategy of building a complete ginseng industry chain, increasing its ginseng reserves through self-cultivation and external procurement[64]. - Future guidance indicates a cautious outlook, with expectations of gradual recovery in revenue growth[145]. Social Responsibility and Governance - The company emphasizes social responsibility, focusing on environmental friendliness, resource conservation, and participation in social welfare activities[76]. - The company has implemented strict internal control systems to protect the rights of shareholders and creditors, ensuring timely disclosure of major information[77]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including a specific emergency plan and regular employee training[75]. - The company has not received any administrative penalties for environmental issues during the reporting period[74]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 28,525[108]. - Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[108]. - The total number of shares is 330,951,600, with 69.91% being unrestricted shares[106]. - There were no changes in the number of shares held by major shareholders during the reporting period[108]. Cash Flow and Financing - The total cash inflow from operating activities was ¥390,266,026.16, while cash outflow was ¥382,315,619.37, resulting in a positive net cash flow[140]. - The company received ¥170,000,000.00 from borrowings, while cash outflow for debt repayment was ¥170,000,000.00, leading to a net cash flow from financing activities of -¥7,331,676.21[142]. - The cash flow from financing activities showed a significant decrease in cash outflow for dividend distribution, which was ¥7,265,076.21 compared to ¥16,709,623.72 in the previous year[142]. Compliance and Accounting - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards[159]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for at least 12 months from the reporting date[160]. - The financial report was approved by the board on August 25, 2022[158]. - The company adheres to the accounting policies and estimates as per the relevant accounting standards[161].

Financial Performance - The company's revenue for Q1 2022 was ¥225,540,617.25, a decrease of 1.55% compared to ¥229,097,736.43 in the same period last year[4] - Net profit attributable to shareholders was ¥27,229,639.30, down 1.93% from ¥27,765,054.54 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥19,705,067.74, representing a decline of 15.81% from ¥23,405,772.17 in the previous year[4] - Total operating revenue for the current period is $225.54 million, a decrease of 1.23% from $229.10 million in the previous period[21] - Operating profit decreased to $33.67 million, down 19.73% from $41.91 million in the previous period[22] - Net profit for the current period is $29.23 million, a decline of 12.93% compared to $33.19 million in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities increased by 32.73% to ¥38,973,399.49, compared to ¥29,363,113.24 in the same period last year[4] - Cash flow from operating activities increased to $38.97 million, up 32.73% from $29.36 million in the previous period[26] - Cash and cash equivalents at the end of the quarter were CNY 200,989,827.14, down from CNY 219,695,016.40[17] - Cash and cash equivalents at the end of the period decreased to $200.99 million, down from $290.24 million in the previous period[27] - The company reported a net cash outflow from financing activities of $31.03 million, compared to an outflow of $12.24 million in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,850,618,838.70, a decrease of 0.48% from ¥2,864,366,655.13 at the end of the previous year[4] - The company's current assets totaled CNY 2,208,310,379.88, slightly down from CNY 2,221,792,551.02 at the start of the year[17] - The total liabilities decreased to CNY 650,352,779.13 from CNY 666,082,205.82[19] - The company's equity attributable to shareholders increased to CNY 2,109,039,378.83 from CNY 2,081,809,739.53[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,823[10] - Basic and diluted earnings per share decreased to $0.0823, down from $0.0839 in the previous period[23] Expenses - Total operating costs increased to $199.83 million, up 2.03% from $194.43 million in the previous period[21] - Financial expenses rose by 98.56% to ¥2,610,477.73, primarily due to decreased interest income and increased interest expenses[8] - Financial expenses increased to $2.61 million, up from $1.31 million in the previous period[22] - Research and development expenses for the current period were $4.34 million, a decrease of 10% from $4.82 million in the previous period[21] Government Support - The company received government subsidies amounting to ¥8,400,380.57 during the reporting period[6] Accounts Receivable and Inventory - The company's accounts receivable increased by 61.76% to ¥2,922,425.05, influenced by an increase in commercial acceptance bills[8] - Accounts receivable rose to CNY 223,010,062.92 from CNY 195,846,007.45, indicating a growth of approximately 13.8%[17] - Inventory levels were reported at CNY 1,593,579,012.74, a slight decrease from CNY 1,596,871,561.48[17] Other Information - The company is addressing issues related to shareholding transparency and has implemented a plan to rectify the situation regarding shareholding disclosures[13] - The company’s short-term borrowings remained stable at CNY 397,864,988.96, compared to CNY 397,862,867.43 at the beginning of the year[18] - The company’s net profit for the first quarter of 2022 is not explicitly stated in the provided documents, but the focus on product inclusion in COVID-19 treatment guidelines suggests potential revenue growth opportunities[14]